healio.com
Chikungunya therapy shows promise in first-in-human study
MUNICH — A monoclonal antibody being studied as a potential therapy for chikungunya virus infection showed potential as both a treatment for the mosquito-borne disease and as pre-exposure prophylaxis to prevent infection, researchers said. Hugh Watson, PhD, president of Quayside Research in Lyon, France, and colleagues studied the mAb, called EVT894, in a first-in-human randomized,